English
简体中文
Total: £ 56.28
Published Date: 2025-06-13 | Pages: 157 | Tables: 147 | Medical Care
In 2024, the global market size of Circulating Tumor Cells was estimated to be worth US$ 2291 million and is forecast to reach approximately US$ 8259 million by 2031 with a CAGR of 20.4% during the forecast period 2025-2031.
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
Global Circulating Tumor Cells main players are Menarini-Silicon Biosystems, Qiagen（Adnagen）, Clearbridge Biomedics, Celsee, Fluidigm. Global top five manufacturers hold a share over 30%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cells, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cells.
The Circulating Tumor Cells market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Circulating Tumor Cells market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Tumor Cells companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Menarini-Silicon Biosystems
Qiagen (Adnagen)
Advanced Cell Diagnostics
ApoCell
Epic Sciences
Greiner Bio-one GmbH
Cynvenio
SurExamBio-Tech
Fluxion Biosciences
Ikonisys
Hangzhou Watson Biotech
Biocept
CytoTrack
Guangzhou Wondfo Biotech
Celsee
Clearbridge Biomedics
ANGLE plc
Segment by Type
CTC Enrichment
CTC Detection
CTC Analysis
Segment by Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Circulating Tumor Cells in global and regional level.
Chapter 3: Detailed analysis of Circulating Tumor Cells company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Circulating Tumor Cells revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Circulating Tumor Cells Product Introduction
1.2 Market by Type
1.2.1 Global Circulating Tumor Cells Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 CTC Enrichment
1.2.3 CTC Detection
1.2.4 CTC Analysis
1.3 Market by Application
1.3.1 Global Circulating Tumor Cells Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Breast Cancer
1.3.3 Prostate Cancer
1.3.4 Colorectal Cancer
1.3.5 Lung Cancer
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Circulating Tumor Cells Market Size Estimates and Forecasts
2.2 Circulating Tumor Cells Market Size by Region: 2024 Versus 2031
2.2.1 Global Circulating Tumor Cells Revenue by Region: 2020-2025
2.2.2 Global Circulating Tumor Cells Revenue Forecast by Region (2026-2031)
2.2.3 Global Circulating Tumor Cells Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Circulating Tumor Cells Revenue by Type (2020-2031)
3.1.2 Global Circulating Tumor Cells Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Circulating Tumor Cells Revenue by Application (2020-2031)
3.2.2 Global Circulating Tumor Cells Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 CTC Enrichment of Circulating Tumor Cells Revenue Market Share by Application
3.3.2 CTC Detection of Circulating Tumor Cells Revenue Market Share by Application
3.3.3 CTC Analysis of Circulating Tumor Cells Revenue Market Share by Application
4 Global Circulating Tumor Cells by Company
4.1 Global Circulating Tumor Cells Revenue by Company (2020-2025)
4.2 Global Circulating Tumor Cells Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Circulating Tumor Cells Companies around the World: Ranking by Revenue
4.3.2 Global Circulating Tumor Cells Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Circulating Tumor Cells Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Circulating Tumor Cells Companies Headquarters & Product Type
4.4.1 Global Circulating Tumor Cells Companies Headquarters
4.4.2 Date of International Companies Enter into Circulating Tumor Cells Market
4.4.3 Global Circulating Tumor Cells Companies Product & Service
4.4.4 CTC Enrichment Revenue Market Share of Circulating Tumor Cells by Company
4.4.5 CTC Detection Revenue Market Share of Circulating Tumor Cells by Company
4.4.6 CTC Analysis Revenue Market Share of Circulating Tumor Cells by Company
4.5 Global Circulating Tumor Cells Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Menarini-Silicon Biosystems
5.1.1 Menarini-Silicon Biosystems Corporation Information
5.1.2 Menarini-Silicon Biosystems Description, Business Overview
5.1.3 Menarini-Silicon Biosystems Circulating Tumor Cells Products Offered
5.1.4 Menarini-Silicon Biosystems Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.1.5 Menarini-Silicon Biosystems Circulating Tumor Cells Revenue by Product in 2024
5.1.6 Menarini-Silicon Biosystems Circulating Tumor Cells Revenue by Application in 2024
5.1.7 Menarini-Silicon Biosystems Circulating Tumor Cells Revenue by Geographic Area in 2024
5.1.8 Menarini-Silicon Biosystems Recent Developments
5.2 Qiagen (Adnagen)
5.2.1 Qiagen (Adnagen) Corporation Information
5.2.2 Qiagen (Adnagen) Description, Business Overview
5.2.3 Qiagen (Adnagen) Circulating Tumor Cells Products Offered
5.2.4 Qiagen (Adnagen) Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.2.5 Qiagen (Adnagen) Circulating Tumor Cells Revenue by Product in 2024
5.2.6 Qiagen (Adnagen) Circulating Tumor Cells Revenue by Application in 2024
5.2.7 Qiagen (Adnagen) Circulating Tumor Cells Revenue by Geographic Area in 2024
5.2.8 Qiagen (Adnagen) Recent Developments
5.3 Advanced Cell Diagnostics
5.3.1 Advanced Cell Diagnostics Corporation Information
5.3.2 Advanced Cell Diagnostics Description, Business Overview
5.3.3 Advanced Cell Diagnostics Circulating Tumor Cells Products Offered
5.3.4 Advanced Cell Diagnostics Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.3.5 Advanced Cell Diagnostics Circulating Tumor Cells Revenue by Product in 2024
5.3.6 Advanced Cell Diagnostics Circulating Tumor Cells Revenue by Application in 2024
5.3.7 Advanced Cell Diagnostics Circulating Tumor Cells Revenue by Geographic Area in 2024
5.3.8 Advanced Cell Diagnostics Recent Developments
5.4 ApoCell
5.4.1 ApoCell Corporation Information
5.4.2 ApoCell Description, Business Overview
5.4.3 ApoCell Circulating Tumor Cells Products Offered
5.4.4 ApoCell Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.4.5 ApoCell Circulating Tumor Cells Revenue by Product in 2024
5.4.6 ApoCell Circulating Tumor Cells Revenue by Application in 2024
5.4.7 ApoCell Circulating Tumor Cells Revenue by Geographic Area in 2024
5.4.8 ApoCell Recent Developments
5.5 Epic Sciences
5.5.1 Epic Sciences Corporation Information
5.5.2 Epic Sciences Description, Business Overview
5.5.3 Epic Sciences Circulating Tumor Cells Products Offered
5.5.4 Epic Sciences Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.5.5 Epic Sciences Circulating Tumor Cells Revenue by Product in 2024
5.5.6 Epic Sciences Circulating Tumor Cells Revenue by Application in 2024
5.5.7 Epic Sciences Circulating Tumor Cells Revenue by Geographic Area in 2024
5.5.8 Epic Sciences Recent Developments
5.6 Greiner Bio-one GmbH
5.6.1 Greiner Bio-one GmbH Corporation Information
5.6.2 Greiner Bio-one GmbH Description, Business Overview
5.6.3 Greiner Bio-one GmbH Circulating Tumor Cells Products Offered
5.6.4 Greiner Bio-one GmbH Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.6.5 Greiner Bio-one GmbH Circulating Tumor Cells Revenue by Product in 2024
5.6.6 Greiner Bio-one GmbH Circulating Tumor Cells Revenue by Application in 2024
5.6.7 Greiner Bio-one GmbH Circulating Tumor Cells Revenue by Geographic Area in 2024
5.6.8 Greiner Bio-one GmbH Recent Developments
5.7 Cynvenio
5.7.1 Cynvenio Corporation Information
5.7.2 Cynvenio Description, Business Overview
5.7.3 Cynvenio Circulating Tumor Cells Products Offered
5.7.4 Cynvenio Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.7.5 Cynvenio Circulating Tumor Cells Revenue by Product in 2024
5.7.6 Cynvenio Circulating Tumor Cells Revenue by Application in 2024
5.7.7 Cynvenio Circulating Tumor Cells Revenue by Geographic Area in 2024
5.7.8 Cynvenio Recent Developments
5.8 SurExamBio-Tech
5.8.1 SurExamBio-Tech Corporation Information
5.8.2 SurExamBio-Tech Description, Business Overview
5.8.3 SurExamBio-Tech Circulating Tumor Cells Products Offered
5.8.4 SurExamBio-Tech Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.8.5 SurExamBio-Tech Circulating Tumor Cells Revenue by Product in 2024
5.8.6 SurExamBio-Tech Circulating Tumor Cells Revenue by Application in 2024
5.8.7 SurExamBio-Tech Circulating Tumor Cells Revenue by Geographic Area in 2024
5.8.8 SurExamBio-Tech Recent Developments
5.9 Fluxion Biosciences
5.9.1 Fluxion Biosciences Corporation Information
5.9.2 Fluxion Biosciences Description, Business Overview
5.9.3 Fluxion Biosciences Circulating Tumor Cells Products Offered
5.9.4 Fluxion Biosciences Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.9.5 Fluxion Biosciences Circulating Tumor Cells Revenue by Product in 2024
5.9.6 Fluxion Biosciences Circulating Tumor Cells Revenue by Application in 2024
5.9.7 Fluxion Biosciences Circulating Tumor Cells Revenue by Geographic Area in 2024
5.9.8 Fluxion Biosciences Recent Developments
5.10 Ikonisys
5.10.1 Ikonisys Corporation Information
5.10.2 Ikonisys Description, Business Overview
5.10.3 Ikonisys Circulating Tumor Cells Products Offered
5.10.4 Ikonisys Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.10.5 Ikonisys Circulating Tumor Cells Revenue by Product in 2024
5.10.6 Ikonisys Circulating Tumor Cells Revenue by Application in 2024
5.10.7 Ikonisys Circulating Tumor Cells Revenue by Geographic Area in 2024
5.10.8 Ikonisys Recent Developments
5.11 Hangzhou Watson Biotech
5.11.1 Hangzhou Watson Biotech Corporation Information
5.11.2 Hangzhou Watson Biotech Description, Business Overview
5.11.3 Hangzhou Watson Biotech Circulating Tumor Cells Products Offered
5.11.4 Hangzhou Watson Biotech Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.11.5 Hangzhou Watson Biotech Circulating Tumor Cells Revenue by Product in 2024
5.11.6 Hangzhou Watson Biotech Circulating Tumor Cells Revenue by Application in 2024
5.11.7 Hangzhou Watson Biotech Circulating Tumor Cells Revenue by Geographic Area in 2024
5.11.8 Hangzhou Watson Biotech Recent Developments
5.12 Biocept
5.12.1 Biocept Corporation Information
5.12.2 Biocept Description, Business Overview
5.12.3 Biocept Circulating Tumor Cells Products Offered
5.12.4 Biocept Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.12.5 Biocept Circulating Tumor Cells Revenue by Product in 2024
5.12.6 Biocept Circulating Tumor Cells Revenue by Application in 2024
5.12.7 Biocept Circulating Tumor Cells Revenue by Geographic Area in 2024
5.12.8 Biocept Recent Developments
5.13 CytoTrack
5.13.1 CytoTrack Corporation Information
5.13.2 CytoTrack Description, Business Overview
5.13.3 CytoTrack Circulating Tumor Cells Products Offered
5.13.4 CytoTrack Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.13.5 CytoTrack Circulating Tumor Cells Revenue by Product in 2024
5.13.6 CytoTrack Circulating Tumor Cells Revenue by Application in 2024
5.13.7 CytoTrack Circulating Tumor Cells Revenue by Geographic Area in 2024
5.13.8 CytoTrack Recent Developments
5.14 Guangzhou Wondfo Biotech
5.14.1 Guangzhou Wondfo Biotech Corporation Information
5.14.2 Guangzhou Wondfo Biotech Description, Business Overview
5.14.3 Guangzhou Wondfo Biotech Circulating Tumor Cells Products Offered
5.14.4 Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.14.5 Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue by Product in 2024
5.14.6 Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue by Application in 2024
5.14.7 Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue by Geographic Area in 2024
5.14.8 Guangzhou Wondfo Biotech Recent Developments
5.15 Celsee
5.15.1 Celsee Corporation Information
5.15.2 Celsee Description, Business Overview
5.15.3 Celsee Circulating Tumor Cells Products Offered
5.15.4 Celsee Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.15.5 Celsee Circulating Tumor Cells Revenue by Product in 2024
5.15.6 Celsee Circulating Tumor Cells Revenue by Application in 2024
5.15.7 Celsee Circulating Tumor Cells Revenue by Geographic Area in 2024
5.15.8 Celsee Recent Developments
5.16 Clearbridge Biomedics
5.16.1 Clearbridge Biomedics Corporation Information
5.16.2 Clearbridge Biomedics Description, Business Overview
5.16.3 Clearbridge Biomedics Circulating Tumor Cells Products Offered
5.16.4 Clearbridge Biomedics Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.16.5 Clearbridge Biomedics Circulating Tumor Cells Revenue by Product in 2024
5.16.6 Clearbridge Biomedics Circulating Tumor Cells Revenue by Application in 2024
5.16.7 Clearbridge Biomedics Circulating Tumor Cells Revenue by Geographic Area in 2024
5.16.8 Clearbridge Biomedics Recent Developments
5.17 ANGLE plc
5.17.1 ANGLE plc Corporation Information
5.17.2 ANGLE plc Description, Business Overview
5.17.3 ANGLE plc Circulating Tumor Cells Products Offered
5.17.4 ANGLE plc Circulating Tumor Cells Revenue and Gross Margin (2020-2025)
5.17.5 ANGLE plc Circulating Tumor Cells Revenue by Product in 2024
5.17.6 ANGLE plc Circulating Tumor Cells Revenue by Application in 2024
5.17.7 ANGLE plc Circulating Tumor Cells Revenue by Geographic Area in 2024
5.17.8 ANGLE plc Recent Developments
6 North America
6.1 North America Circulating Tumor Cells Market Size YoY Growth 2020-2031
6.2 North America Circulating Tumor Cells Market Facts & Figures by Country (2020-2031)
6.3 North America Circulating Tumor Cells Revenue by Type (2020-2025)
6.4 North America Circulating Tumor Cells Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Circulating Tumor Cells Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Circulating Tumor Cells Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Circulating Tumor Cells Revenue by Type (2020-2025)
7.4 Asia-Pacific Circulating Tumor Cells Revenue by Application (2020-2025)
8 Europe
8.1 Europe Circulating Tumor Cells Market Size YoY Growth 2020-2031
8.2 Europe Circulating Tumor Cells Market Facts & Figures by Country (2020-2031)
8.3 Europe Circulating Tumor Cells Revenue by Type (2020-2025)
8.4 Europe Circulating Tumor Cells Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Circulating Tumor Cells Market Size YoY Growth 2020-2031
9.2 Latin America Circulating Tumor Cells Market Facts & Figures by Country (2020-2031)
9.3 Latin America Circulating Tumor Cells Revenue by Type (2020-2025)
9.4 Latin America Circulating Tumor Cells Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Circulating Tumor Cells Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Circulating Tumor Cells Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Circulating Tumor Cells Revenue by Type (2020-2025)
10.4 Middle East and Africa Circulating Tumor Cells Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Circulating Tumor Cells Supply Chain Analysis
11.2 Circulating Tumor Cells Key Raw Materials and Upstream Suppliers
11.3 Circulating Tumor Cells Clients Analysis
11.4 Circulating Tumor Cells Sales Channel and Sales Model Analysis
11.4.1 Circulating Tumor Cells Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Circulating Tumor Cells Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Circulating Tumor Cells Distributors
12 Circulating Tumor Cells Market Dynamics
12.1 Circulating Tumor Cells Industry Trends
12.2 Circulating Tumor Cells Market Drivers
12.3 Circulating Tumor Cells Market Challenges
12.4 Circulating Tumor Cells Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Circulating Tumor Cells Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Circulating Tumor Cells Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Circulating Tumor Cells Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Circulating Tumor Cells Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Circulating Tumor Cells Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Circulating Tumor Cells Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Circulating Tumor Cells Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Circulating Tumor Cells Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Circulating Tumor Cells Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Circulating Tumor Cells Revenue by Company (2020-2025) & (US$ Million)
Table 11. Circulating Tumor Cells Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Circulating Tumor Cells Players by Revenue (US$ Million) in 2024
Table 13. Global Circulating Tumor Cells Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Circulating Tumor Cells by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cells as of 2024)
Table 15. Global Circulating Tumor Cells Companies Headquarters
Table 16. Date of International Companies Enter into Circulating Tumor Cells Market
Table 17. Global Circulating Tumor Cells Companies Product & Service
Table 18. Global Circulating Tumor Cells Mergers & Acquisitions, Expansion Plans
Table 19. Menarini-Silicon Biosystems Corporation Information
Table 20. Menarini-Silicon Biosystems Description and Business Overview
Table 21. Menarini-Silicon Biosystems Circulating Tumor Cells Product
Table 22. Menarini-Silicon Biosystems Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Menarini-Silicon Biosystems Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 24. Menarini-Silicon Biosystems Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 25. Menarini-Silicon Biosystems Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 26. Menarini-Silicon Biosystems Recent Developments
Table 27. Qiagen (Adnagen) Corporation Information
Table 28. Qiagen (Adnagen) Description and Business Overview
Table 29. Qiagen (Adnagen) Circulating Tumor Cells Product
Table 30. Qiagen (Adnagen) Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Qiagen (Adnagen) Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 32. Qiagen (Adnagen) Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 33. Qiagen (Adnagen) Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 34. Qiagen (Adnagen) Recent Developments
Table 35. Advanced Cell Diagnostics Corporation Information
Table 36. Advanced Cell Diagnostics Description and Business Overview
Table 37. Advanced Cell Diagnostics Circulating Tumor Cells Product
Table 38. Advanced Cell Diagnostics Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Advanced Cell Diagnostics Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 40. Advanced Cell Diagnostics Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 41. Advanced Cell Diagnostics Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 42. Advanced Cell Diagnostics Recent Developments
Table 43. ApoCell Corporation Information
Table 44. ApoCell Description and Business Overview
Table 45. ApoCell Circulating Tumor Cells Product
Table 46. ApoCell Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. ApoCell Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 48. ApoCell Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 49. ApoCell Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 50. ApoCell Recent Developments
Table 51. Epic Sciences Corporation Information
Table 52. Epic Sciences Description and Business Overview
Table 53. Epic Sciences Circulating Tumor Cells Product
Table 54. Epic Sciences Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Epic Sciences Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 56. Epic Sciences Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 57. Epic Sciences Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 58. Epic Sciences Recent Developments
Table 59. Greiner Bio-one GmbH Corporation Information
Table 60. Greiner Bio-one GmbH Description and Business Overview
Table 61. Greiner Bio-one GmbH Circulating Tumor Cells Product
Table 62. Greiner Bio-one GmbH Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Greiner Bio-one GmbH Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 64. Greiner Bio-one GmbH Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 65. Greiner Bio-one GmbH Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 66. Greiner Bio-one GmbH Recent Developments
Table 67. Cynvenio Corporation Information
Table 68. Cynvenio Description and Business Overview
Table 69. Cynvenio Circulating Tumor Cells Product
Table 70. Cynvenio Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. Cynvenio Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 72. Cynvenio Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 73. Cynvenio Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 74. Cynvenio Recent Developments
Table 75. SurExamBio-Tech Corporation Information
Table 76. SurExamBio-Tech Description and Business Overview
Table 77. SurExamBio-Tech Circulating Tumor Cells Product
Table 78. SurExamBio-Tech Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. SurExamBio-Tech Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 80. SurExamBio-Tech Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 81. SurExamBio-Tech Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 82. SurExamBio-Tech Recent Developments
Table 83. Fluxion Biosciences Corporation Information
Table 84. Fluxion Biosciences Description and Business Overview
Table 85. Fluxion Biosciences Circulating Tumor Cells Product
Table 86. Fluxion Biosciences Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. Fluxion Biosciences Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 88. Fluxion Biosciences Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 89. Fluxion Biosciences Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 90. Fluxion Biosciences Recent Developments
Table 91. Ikonisys Corporation Information
Table 92. Ikonisys Description and Business Overview
Table 93. Ikonisys Circulating Tumor Cells Product
Table 94. Ikonisys Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. Ikonisys Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 96. Ikonisys Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 97. Ikonisys Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 98. Ikonisys Recent Developments
Table 99. Hangzhou Watson Biotech Corporation Information
Table 100. Hangzhou Watson Biotech Description and Business Overview
Table 101. Hangzhou Watson Biotech Circulating Tumor Cells Product
Table 102. Hangzhou Watson Biotech Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Hangzhou Watson Biotech Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 104. Hangzhou Watson Biotech Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 105. Hangzhou Watson Biotech Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 106. Hangzhou Watson Biotech Recent Developments
Table 107. Biocept Corporation Information
Table 108. Biocept Description and Business Overview
Table 109. Biocept Circulating Tumor Cells Product
Table 110. Biocept Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 111. Biocept Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 112. Biocept Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 113. Biocept Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 114. Biocept Recent Developments
Table 115. CytoTrack Corporation Information
Table 116. CytoTrack Description and Business Overview
Table 117. CytoTrack Circulating Tumor Cells Product
Table 118. CytoTrack Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 119. CytoTrack Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 120. CytoTrack Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 121. CytoTrack Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 122. CytoTrack Recent Developments
Table 123. Guangzhou Wondfo Biotech Corporation Information
Table 124. Guangzhou Wondfo Biotech Description and Business Overview
Table 125. Guangzhou Wondfo Biotech Circulating Tumor Cells Product
Table 126. Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 127. Guangzhou Wondfo Biotech Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 128. Guangzhou Wondfo Biotech Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 129. Guangzhou Wondfo Biotech Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 130. Guangzhou Wondfo Biotech Recent Developments
Table 131. Celsee Corporation Information
Table 132. Celsee Description and Business Overview
Table 133. Celsee Circulating Tumor Cells Product
Table 134. Celsee Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 135. Celsee Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 136. Celsee Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 137. Celsee Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 138. Celsee Recent Developments
Table 139. Clearbridge Biomedics Corporation Information
Table 140. Clearbridge Biomedics Description and Business Overview
Table 141. Clearbridge Biomedics Circulating Tumor Cells Product
Table 142. Clearbridge Biomedics Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Clearbridge Biomedics Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 144. Clearbridge Biomedics Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 145. Clearbridge Biomedics Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 146. Clearbridge Biomedics Recent Developments
Table 147. ANGLE plc Corporation Information
Table 148. ANGLE plc Description and Business Overview
Table 149. ANGLE plc Circulating Tumor Cells Product
Table 150. ANGLE plc Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2020-2025)
Table 151. ANGLE plc Revenue Proportion of Circulating Tumor Cells by Product in 2024
Table 152. ANGLE plc Revenue Proportion of Circulating Tumor Cells by Application in 2024
Table 153. ANGLE plc Revenue Proportion of Circulating Tumor Cells by Geographic Area in 2024
Table 154. ANGLE plc Recent Developments
Table 155. North America Circulating Tumor Cells Revenue by Country (2020-2025) & (US$ Million)
Table 156. North America Circulating Tumor Cells Revenue by Country (2026-2031) & (US$ Million)
Table 157. North America Circulating Tumor Cells Revenue by Type (2020-2025) & (US$ Million)
Table 158. North America Circulating Tumor Cells Revenue by Application (2020-2025) & (US$ Million)
Table 159. Asia-Pacific Circulating Tumor Cells Revenue by Region (2020-2025) & (US$ Million)
Table 160. Asia-Pacific Circulating Tumor Cells Revenue by Region (2026-2031) & (US$ Million)
Table 161. Asia-Pacific Circulating Tumor Cells Revenue by Type (2020-2025) & (US$ Million)
Table 162. Asia-Pacific Circulating Tumor Cells Revenue by Application (2020-2025) & (US$ Million)
Table 163. Europe Circulating Tumor Cells Revenue by Country (2020-2025) & (US$ Million)
Table 164. Europe Circulating Tumor Cells Revenue by Country (2026-2031) & (US$ Million)
Table 165. Europe Circulating Tumor Cells Revenue by Type (2020-2025) & (US$ Million)
Table 166. Europe Circulating Tumor Cells Revenue by Application (2020-2025) & (US$ Million)
Table 167. Latin America Circulating Tumor Cells Revenue by Country (2020-2025) & (US$ Million)
Table 168. Latin America Circulating Tumor Cells Revenue by Country (2026-2031) & (US$ Million)
Table 169. Latin America Circulating Tumor Cells Revenue by Type (2020-2025) & (US$ Million)
Table 170. Latin America Circulating Tumor Cells Revenue by Application (2020-2025) & (US$ Million)
Table 171. Middle East and Africa Circulating Tumor Cells Revenue by Country (2020-2025) & (US$ Million)
Table 172. Middle East and Africa Circulating Tumor Cells Revenue by Country (2026-2031) & (US$ Million)
Table 173. Middle East and Africa Circulating Tumor Cells Revenue by Type (2020-2025) & (US$ Million)
Table 174. Middle East and Africa Circulating Tumor Cells Revenue by Application (2020-2025) & (US$ Million)
Table 175. Circulating Tumor Cells Key Raw Materials, Industry Status and Trend
Table 176. Circulating Tumor Cells Key Raw Materials and Upstream Suppliers
Table 177. Circulating Tumor Cells Clients Status and Trend
Table 178. Circulating Tumor Cells Typical Clients
Table 179. Circulating Tumor Cells Distributors
Table 180. Circulating Tumor Cells Market Trends
Table 181. Circulating Tumor Cells Market Drivers
Table 182. Circulating Tumor Cells Market Challenges
Table 183. Circulating Tumor Cells Market Restraints
Table 184. Research Programs/Design for This Report
Table 185. Key Data Information from Secondary Sources
Table 186. Key Data Information from Primary Sources
List of Figures
Figure 1. Circulating Tumor Cells Product Picture
Figure 2. Global Circulating Tumor Cells Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Circulating Tumor Cells Revenue Market Share by Type in 2024 & 2031
Figure 4. CTC Enrichment Product Picture
Figure 5. CTC Detection Product Picture
Figure 6. CTC Analysis Product Picture
Figure 7. Global Circulating Tumor Cells Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 8. Global Circulating Tumor Cells Revenue Market Share by Application in 2024 & 2031
Figure 9. Breast Cancer
Figure 10. Prostate Cancer
Figure 11. Colorectal Cancer
Figure 12. Lung Cancer
Figure 13. Others
Figure 14. Circulating Tumor Cells Report Years Considered
Figure 15. Global Circulating Tumor Cells Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Circulating Tumor Cells Market Size (2020-2031) & (US$ Million)
Figure 17. Global Circulating Tumor Cells Market Size Market Share by Region: 2024 Versus 2031
Figure 18. Global Circulating Tumor Cells Revenue Market Share by Region (2020-2031)
Figure 19. Global Circulating Tumor Cells Revenue Market Share Forecast by Type (2020-2031)
Figure 20. Global Circulating Tumor Cells Revenue Market Share Forecast by Application (2020-2031)
Figure 21. CTC Enrichment of Circulating Tumor Cells Revenue Market Share by Application, 2024 VS 2031
Figure 22. CTC Detection of Circulating Tumor Cells Revenue Market Share by Application, 2024 VS 2031
Figure 23. CTC Analysis of Circulating Tumor Cells Revenue Market Share by Application, 2024 VS 2031
Figure 24. Circulating Tumor Cells Revenue Share by Company (2024)
Figure 25. Circulating Tumor Cells Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 26. CTC Enrichment Revenue Proportion by Company in 2024
Figure 27. CTC Detection Revenue Proportion by Company in 2024
Figure 28. CTC Analysis Revenue Proportion by Company in 2024
Figure 29. North America Circulating Tumor Cells Revenue 2020-2031 (US$ Million)
Figure 30. North America Circulating Tumor Cells Revenue Market Share by Type (2020-2025)
Figure 31. North America Circulating Tumor Cells Revenue Market Share by Application (2020-2025)
Figure 32. Asia-Pacific Circulating Tumor Cells Revenue 2020-2031 (US$ Million)
Figure 33. Asia-Pacific Circulating Tumor Cells Revenue Market Share by Region (2020-2031)
Figure 34. Asia-Pacific Circulating Tumor Cells Revenue Market Share by Type (2020-2025)
Figure 35. Asia-Pacific Circulating Tumor Cells Revenue Market Share by Application (2020-2025)
Figure 36. Europe Circulating Tumor Cells Revenue Growth Rate 2020-2031 (US$ Million)
Figure 37. Europe Circulating Tumor Cells Revenue Market Share by Country (2020-2031)
Figure 38. Europe Circulating Tumor Cells Revenue Market Share by Type (2020-2025)
Figure 39. Europe Circulating Tumor Cells Revenue Market Share by Application (2020-2025)
Figure 40. Latin America Circulating Tumor Cells Revenue Growth Rate 2020-2031 (US$ Million)
Figure 41. Latin America Circulating Tumor Cells Revenue Market Share by Country (2020-2031)
Figure 42. Latin America Circulating Tumor Cells Revenue Market Share by Type (2020-2025)
Figure 43. Latin America Circulating Tumor Cells Revenue Market Share by Application (2020-2025)
Figure 44. Middle East and Africa Circulating Tumor Cells Revenue Growth Rate 2020-2031 (US$ Million)
Figure 45. Middle East and Africa Circulating Tumor Cells Revenue Market Share by Country (2020-2031)
Figure 46. Middle East and Africa Circulating Tumor Cells Revenue Market Share by Type (2020-2025)
Figure 47. Middle East and Africa Circulating Tumor Cells Revenue Market Share by Application (2020-2025)
Figure 48. Circulating Tumor Cells Supply Chain (Upstream and Downstream Market)
Figure 49. Global Production Market Share of Circulating Tumor Cells Raw Materials by Region in 2024
Figure 50. Circulating Tumor Cells Distribution Channels
Figure 51. Global Circulating Tumor Cells Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 52. Global Circulating Tumor Cells Percentage 2020-2031: Online Sales VS Offline Sales
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
